Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.

Lijun Wang,Hongwei Wang,Yong Cui,Ming Liu,Kemin Jin,Da Xu,Kun Wang,Baocai Xing

Frontiers in Oncology（2023）

引用 0|浏览3

暂无评分

摘要

Sintilimab plus Lenvatinib is safe and feasible for the conversion treatment of intermediate to locally advanced HCC initially unsuitable for surgical resection.

查看译文

关键词

conversion therapy,hepatocellular carcinoma,lenvatinib,resection,sintilimab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要